WHO ICTRP trial
Phase I clinical trial of personalized neoantigen peptides combined with seed…
ChiCTR-INR-16010125 · Chinese Clinical Trial Registry (ChiCTR) · Recruiting
Key facts
| Trial ID | ChiCTR-INR-16010125 |
|---|---|
| Public title | Phase I clinical trial of personalized neoantigen peptides combined with seed implantation in the treatment of advanced chest malignant tumor |
| Scientific title | Phase I clinical trial of personalized neoantigen peptides combined with seed implantation in the treatment of advanced chest malignant tumor |
| Primary sponsor | Tianjin Beichen Hospital |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Recruiting |
| Study type | Interventional study |
| Phase | New Treatment Measure Clinical Study |
| Countries | China |
| Conditions | Chest malignant tumor |
| Interventions | Control group:125I need implantation therapy;Study group:125I need implantation therapy combined with personalized neoantigen peptides once a week, 12 weeks for a course of treatment |
| Registration date | Dec 11, 2016 |
| Target size | Control group:50;Study group:50 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: